Drug profile · INN
tedizolid phosphate
SIVEXTRO
tedizolid phosphate (SIVEXTRO) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tedizolid phosphate
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
tedizolid phosphate (SIVEXTRO) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tedizolid phosphate?
tedizolid phosphate (SIVEXTRO) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tedizolid phosphate?
SIVEXTRO is a marketed brand name for tedizolid phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tedizolid phosphate?
tedizolid phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.